You are here

AETC ShareSpot: New HIV Meds Updates

Thursday, August 30, 2018

TargetHIV

From the AETC ShareSpot - Three new HIV Meds Updates blog stories summarize findings presented at AIDS 2018.

They include the following:

  • Results of the U=U in PARTNER2 Study of MSM
  • Results of 2-drug ARV regimen studies: Dolutegravir + 3TC in Initial Therapy
  • The first FDA approved protease inhibitor-containing, single-tablet regimen: Darunavir/Cobicistat/FTC/TAF, More Data from EMERALD Switch Study

HIV Meds Updates are written by Susa Coffey, MD, Co-investigator and Medical Editor of the AETC NCRC and UCSF CHI, and stories are posted as new HIV medication information becomes available.

See more sources for AIDS 2018 Updates

Total views: 167